Donislecel (Lantidra); first stem cell therapy, a cutting-edge therapeutic option for type 1 diabetes, but would it be beneficial in the riskiest region of the world?

Iqbal, Amna; Sheikh, Ayesha

doi:10.1097/gh9.0000000000000259

International Journal of Surgery: Global Health

2023

DOI: 10.1097/gh9.0000000000000259

|View full text |Cite

Donislecel (Lantidra); first stem cell therapy, a cutting-edge therapeutic option for type 1 diabetes, but would it be beneficial in the riskiest region of the world?

Amna Iqbal,

Ayesha Sheikh

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Lantidra: Cell Therapy for Treatment of Type 1 Diabetes Mellitus

B. Bharambe,

Jawarkar

2024

AJPR

View full text Add to dashboard Cite

The more recent cell treatment for type 1 Diabetes is called lantidra. Lantidra has recently received approval to treat type 1 Diabetes mellitus. The first allogeneic (deceased donor) pancreatic islet cell therapy, lantidra (donislecel), was approved by the FDA Centre for Biologics Evaluation and Research (CBER) on June 28, 2023. It is intended to treat adults with type 1 diabetes who, despite current management, do not achieve target glycosylated hemoglobin levels due to recurrent episodes of severe hypoglycemia. The editorial’s goal is to draw attention to the growing impact of type 1 diabetes on the world’s health, discuss earlier attempts at pancreatic transplant techniques, and announces the first regulatory approval of a revolutionary transplant strategy called allogeneic pancreatic islet beta cell infusion.

show abstract

Lantidra: Cell Therapy for Treatment of Type 1 Diabetes Mellitus

B. Bharambe,

Jawarkar

2024

AJPR

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Donislecel (Lantidra); first stem cell therapy, a cutting-edge therapeutic option for type 1 diabetes, but would it be beneficial in the riskiest region of the world?

Cited by 1 publication

References 5 publications

Lantidra: Cell Therapy for Treatment of Type 1 Diabetes Mellitus

Lantidra: Cell Therapy for Treatment of Type 1 Diabetes Mellitus

Contact Info

Product

Resources

About